Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Schizophrenia is a common debilitating disorder characterized by significant impairments in how reality is perceived, combined with behavioural changes. In this review, we describe the lurasidone development programme for adult and paediatric patients. Both the pharmacokinetic and pharmacodynamic ch...

Full description

Bibliographic Details
Authors: Guilera, Teresa, Chart Pascual, Juan Pablo, Blasco, Maria del Carmen, Calvo Estopiñán, Pilar, Piernas González, Rubén Asensio, Ramírez Martínez, Isabel, Rodríguez Moyano, Cristóbal, Prieto Pérez, Rita, Gabarda-Inat, Irene, Prados-Ojeda, Juan L., Diaz-Marsà, Marina, Martín-Carrasco, Manuel
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/464339
Online Access:https://doi.org/10.7573/dic.2022-10-1
https://hdl.handle.net/10459.1/464339
Access Level:Open access
Keyword:Case studies
Clinical trials
Lurasidone
Realworld data
Schizophrenia
Description
Summary:Schizophrenia is a common debilitating disorder characterized by significant impairments in how reality is perceived, combined with behavioural changes. In this review, we describe the lurasidone development programme for adult and paediatric patients. Both the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited. In addition, pivotal clinical studies conducted on both adults and children are summarized. Several clinical cases, which demonstrate the role of lurasidone in real-world practice, are also presented. Current clinical guidelines recommend lurasidone as the first-line treatment in the acute and long-term management of schizophrenia in both adult and paediatric populations.

Similar Items